Immunovaccine Inc.

Immunovaccine Inc.

March 31, 2015 07:00 ET

Immunovaccine to Present at World Vaccine Congress 2015

HALIFAX, NOVA SCOTIA--(Marketwired - March 31, 2015) - Immunovaccine Inc. ("Immunovaccine") (TSX:IMV), a clinical stage vaccine and immunotherapy company, today announced that its chief executive officer, Marc Mansour, Ph.D., will make a presentation and participate in a panel discussion at the World Vaccine Congress 2015. The conference will take place April 7-9, 2015 at the Walter E. Washington Convention Center in Washington D.C.

Dr. Mansour's presentation will highlight the clinical activity observed to date with the Company's lead cancer vaccine, DPX-Survivac, and the ability of the therapy to drive robust poly-functional CD8+ T cell responses. These findings support the mechanism of action of DPX-Survivac in the treatment of cancer. He will also discuss data that demonstrates the synergy of T cell activation and T cell modulation strategies, providing the rationale for next generation combination cancer immunotherapies.

Additionally, Dr. Mansour will participate in a panel discussion aimed at identifying key strategies for combining new adjuvants, delivery systems, vaccine vectors and antigen discovery to support development of the next generation of cancer vaccines.

Details of Dr. Mansour's presentation are as follows:

Title: Enhancing the therapeutic benefit of PD-1/ PDL-1 blockade with DPX-Survivac induced T cell activation - broadening the potential of immunotherapy

Track: Cancer & Immunotherapy

Date: Wednesday, April 8, 2015

Time: 2:40 p.m. (Eastern)

Details of Dr. Mansour's panel discussion are as follows:

Title: What is the future of cancer vaccines and what do we expect from the next-generation of vaccines?

Track: Cancer & Immunotherapy

Date: Wednesday, April 8, 2015

Time: 5:40 p.m. (Eastern)

About DepoVax

DepoVax is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the potential for single-dose effectiveness. The DepoVax platform is flexible and can be used with a broad range of target antigens for preventative or therapeutic applications. The technology is designed to be commercially scalable, with the potential for years of shelf life stability.

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in both ovarian cancer and glioblastoma (brain cancer), with Immunovaccine also exploring additional studies in other indications including lymphoma and recurrent ovarian cancer. The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), anthrax and Ebola virus.

Connect at

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neither TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information